

From: kate dawson/cambridge/biogenidec;nsf;kate.dawson@biogenidec.com;smtp
Sent: Tue Nov 21 2006 16:01:32 EST
To: [REDACTED]
Subject: Re: BG00012 Phase 3 Clinical Trials

Dear Professor [REDACTED]

Thank you for your reply and acceptance of this offer. As it is already quite late in Poland, I will try to contact you tomorrow.

I am looking forward to speaking with you and I am glad you will be a member of this committee.

Thank you

Kate

Kate Dawson M.D.
Associate Director
Clinical Development, Neurology
biogen idec
office 617 914-6377
fax 617 679-3518

NOTE All information contained in this communication is CONFIDENTIAL.

[REDACTED]
21-Nov-2006 02:23 PM

Please respond to

[REDACTED]
Message Size: 4.5 KB

To
Kate Dawson <kate.dawson@biogenidec.com>
cc

Subject
Re: BG00012 Phase 3 Clinical Trials

Dear Dr. Dawson,

Thank you for inviting me to the advisory committee for the 109 MS 301 study. I would be pleased to work with you and Biogen. My contact telephone numbers are:

[REDACTED]

Looking forward to hearing from you.

[REDACTED]

Kate Dawson napisal(a):

>

> Dear Dr. [REDACTED]

>

[REDACTED]

>

> I am a neurologist and the Biogen Idec Medical Director for the BG12 Phase 3 Clinical Trials. I am writing because I would like to speak with you about participating on the advisory committee for 109 MS 301, the placebo-controlled, 2-year study of two doses of BG12 for patients with RRMS.

>

> You have been highly recommended for this position by Prof. [REDACTED]

> who is the Coordinating/Lead Principle Investigator for this trial,
> and Prof. [REDACTED] who will also be an advisory committee
> member. Biogen Idec is always looking to work with leaders in the MS
> field, and I would welcome the opportunity to discuss the clinical
> trial design with you, and answer any questions you might have.
>
> Therefore, I was hoping you could provide me with a way and a
> suggested time to contact you, or alternately you can contact me at
> the numbers listed below (My time zone is six hours behind yours).
>
> Thanks in advance for your time and consideration of this matter, and
> I hope that this program can benefit from your participation.
>
>
> Best Regards,
>
>
> Kate Dawson M.D.
> Associate Director
> Clinical Development, Neurology
> biogen idec
> office 617 914-6377
> fax 617 679-3518
>
> NOTE All information contained in this communication is CONFIDENTIAL.
>